Mekophar (MKP) Fined VND 92.5M by State Securities Inspector for Disclosure Violations
This Aveluro analysis covers MKP on UPCOM in the Health Care sector. The classified event type is legal action, with negative sentiment and a deterministic market-impact score of 4.8/10. Aveluro classifies this story as a negative catalyst and risk signal for the affected stock. Source coverage came from CafeF - Thị trường chứng khoán, classified as a primary/top-tier source.
Key Facts
Caveat: Not investment advice. · How Aveluro computed this: Aveluro combines extracted event facts, source credibility, ticker context, and market data. Scores are deterministic research signals, not recommendations.
Overview
Vietnam’s State Securities Inspector fined CTCP Hóa - Dược phẩm Mekophar (UPCOM: MKP) VND 92.5 million for breaching disclosure deadlines on the HNX website, covering annual reports, audited financial statements and profit-variance explanations. Geleximco – CTCP received a separate VND 92.5 million penalty for failing to submit bond-related documents to HNX. The action puts governance and reporting quality at Mekophar back in focus for UPCOM investors.
Key Facts
- Decision No. 602/QĐ-XPHC, dated 14/10/2026, fines Mekophar VND 92.5 million under point b, clause 4, Article 42 of Decree 156/2020/NĐ-CP, as amended by Decree 306/2025/NĐ-CP.
- Mekophar filed several documents fewer than 15 days late, including the 2024 annual report, the 2025 annual report and explanations of post-tax profit movements in the 2025 audited financial statements.
- Mekophar filed other documents 15 days or more late, including explanations for Q2/2024 losses, reviewed H1/2024 profit variances, and the English-language 2024 audited separate and consolidated financial statements.
- The company also delayed disclosure of the explanation for its Q1/2025 swing from profit to loss in both separate and consolidated statements.
- Mekophar was additionally late publishing the 2026 annual general meeting minutes and related English-language meeting documents.
- Decision No. 600/QĐ-XPHC, dated 13/10/2026, fined Geleximco – CTCP VND 92.5 million for not sending HNX multiple bond-related documents.
- Geleximco’s omissions span 2020 to H1/2024, including audited 2022 bond-proceeds usage reports, semi-annual and full-year 2023 capital-use reports, and H1/2024 principal and interest payment updates.
What Happened
The State Securities Inspector issued Decision No. 602/QĐ-XPHC on 14/10/2026 against CTCP Hóa - Dược phẩm Mekophar, listed on UPCOM under ticker MKP. The regulator found the company breached disclosure timing rules on the HNX website, with violations split between documents filed under 15 days late and those filed 15 days or more late. The shorter delays covered the 2024 and 2025 annual reports and explanations tied to post-tax profit swings in the 2025 audited statements, including cases where profit moved 10% or more year-on-year or where audited figures differed 5% or more from pre-audit numbers.
The longer delays covered a broader set of filings: explanations for Q2/2024 losses, reviewed H1/2024 profit variances, the English-language 2024 audited separate and consolidated financial statements, and the explanation for the Q1/2025 swing from profit to loss. Mekophar also filed the 2026 annual general meeting minutes and English meeting materials late. Separately, Decision No. 600/QĐ-XPHC on 13/10/2026 fined Geleximco – CTCP VND 92.5 million for failing to send HNX documents on its financial position, use of bond-issuance proceeds and payment obligations to bondholders, spanning 2020 through H1/2024.
Market Context
MKP closed at VND 25,100 on 13/10/2026 on UPCOM, the Hanoi exchange’s unlisted public company segment. UPCOM names typically carry thinner liquidity and lighter analyst coverage than HOSE or HNX listings, so disclosure lapses can weigh more heavily on perceived governance quality. The fine itself is small in absolute terms, equivalent to roughly USD 3,700, but it follows a pattern of late filings tied to loss periods and profit volatility, which is the more relevant signal for a pharmaceutical manufacturer navigating margin pressure.
Strategic Significance
For long-term holders, the core issue is not the VND 92.5 million penalty but the reporting cadence behind it. Repeated delays around loss explanations, audited-versus-unaudited gaps and AGM documentation suggest internal reporting capacity or controls that lag the standards expected of a listed manufacturer. In Vietnamese pharma, where tender participation, hospital supply contracts and partnership credibility depend on clean financials, persistent disclosure slippage can affect commercial relationships as much as investor sentiment. The parallel Geleximco penalty underscores that the State Securities Inspector is applying the same enforcement template across issuers and bond-market participants.
What to Watch
- Mekophar’s Q3/2026 financial statements and whether they are filed within the regulatory deadline.
- The 2026 annual general meeting follow-up filings, including any remaining English-language documents.
- Audited 2026 results and whether the auditor flags internal control or going-concern language.
- Any additional State Securities Inspector decisions or HNX reminders referencing MKP.
- Updates on Geleximco’s outstanding bond payment disclosures, given the unresolved 2020-2024 document gaps.